Tag: Hemispherx BioPharma

  • Stocks News To Watch (SNT, NAK, CGR, HEB, AZK)

    Stocks In The News (SNT, NAK, CGR, HEB, AZK)

    Senesco Technologies, Inc. (NYSEAMEX:SNT) announced the results from the completed non-clinical study of SNS01-T in combination of lenalidomide in a model of multiple myeloma. Combining SNS01-T treatment with lenalidomide, or (the active ingredient in REVLIMID marketed by Celgene Corporation, inhibits tumor growth more effectively than either drug alone.

    Northern Dynasty Minerals Ltd. (USA) (NYSEAMEX:NAK), on August 7, 2012, retains senior US political and scientific representatives. On behalf of Northern Dynasty Minerals and its shareholders, prominent Washington DC-based regulatory lawyer Thomas Collier and National Academy of Engineering member Dr. Michael Kavanaugh delivered testimony today in Anchorage, Alaska to the external peer review panel that is evaluating the US Environmental Protection Agency’s (EPA) draft Bristol Bay Watershed Assessment (BBWA) report.

    Claude Resources Inc. (USA) (NYSEAMEX:CGR) cut its full-year production forecast after the company’s second-quarter profit fell steeply due to higher costs and a fall in ore quality. The company’s net profit fell to C$679,000 ($634,700), or a breakeven per share, from C$5.2 million, or 3 Canadian cents per share, a year earlier. Revenue rose 10% to C$20.1 million on higher gold prices.

    Additionally, the company also said it expects per-unit cash costs to be higher by 10% in 2012.

    Hemispherx BioPharma, Inc (NYSEAMEX:HEB), on August 8, 2012, announced its financial results for the three months ended June 30, 2012. The net loss for the period (including non-cash effects) was $3,000,000 or $(0.02) per share, as compared to a net loss of $2,294,000 or ($0.02) per share for the same period in 2011. The net comprehensive loss for the period was $2,786,000, as compared to a net comprehensive loss of $3,389,000 for the same period in 2011.

    Aurizon Mines Ltd.(USA) (NYSEAMEX:AZK) price target was lowered by analysts at Desjardins Securities from $6.75 to $6.25 and the firm currently has a “buy” rating on the stock. The company is a Canada-based gold producer with operations and development activities in the Abitibi region of northwestern Quebec.